Search for a trial

Indocyanine green dye in surgical treatment of laryngeal cancer: perfusion assessment to identify patients at risk for complications

Primary Objective: We want to estimate cut off values for clinically appropriate hypoperfusion of the pharyngeal mucosa and the skin in the neck. Secondary Objective: We want to compare perfusion rate of PTL to perfusion rate in STL in order to…

68Ga-SATO in paediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study - GAP NBL study*

This study has been transitioned to CTIS with ID 2024-513843-10-00 check the CTIS register for the current data. Primary objective: Assess the short term safety and tolerability of 68Ga-SATO in pediatric patients with NBLSecondary objectives: -…

Exploring new imaging opportunities using a large axial field of view PET-CT system

To explore the feasibility and opportunities for new imaging procedures, of relevance of Amsterdam UMC prioritized areas, that a ultra-high sensitivity total body PET-CT system can offer for improving diagnosis and dose reduction.The protocol…

The effect of (chemo- or bio)radiation on functional capacity, fatigue and quality of life in patients with head and neck cancer: a trial within cohorts, the VITAL study.

Primary Objective: - To determine and compare physical performance in patients with HNC with and without an exercise intervention.Secondary Objective(s): - To determine and compare muscle strength in patients with HNC with and without an exercise…

Non-invasive assessment of oral leukoplakia and adjacent tissue

Our primary objective is to determine how often and to what extent potentially pre-malignant oral fields extend beyond their visible lesion. If those "underestimated" lesions have a greater chance to recur, narrow band imaging-guided…

A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)

Primary objective:To evaluate the efficacy of depemokimab 100mg SC + SoC compared to placebo + SoC at Week 52 in participants with a diagnosis of CRSwNP.Secondary Objectives:To evaluate the efficacy of depemokimab 100 mg SC + SoC compared to placebo…

A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin

This study has been transitioned to CTIS with ID 2023-508528-36-00 check the CTIS register for the current data. The purpose of this study is to demonstrate improvement in Disease-Free Survival (DFS) with xevinapant compared to placebo when added to…

App Supported toxicity Surveilance using non-Invasive wearables during Systemic cancer Treatment.

The objective of this study is to:1) explore the feasibility (recruitment, adherence, and absence of major technical problems) of using both medical-grade and consumer grade wearables for continuous measurement of physical activity, posture, balance…

Expression of chemokine receptors upon doxorubicin treatment in breast cancer and sarcoma patients.

To get a better understanding of the kinetics of the expression of CXCR1, CXCR2 and the CXCR1/2 ligands (including IL-8), blood samples of patients with breast cancer or sarcoma will be collected at different timepoints. We expect that with these…

A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

This first-in-man study will investigate the safety and tolerability as well as establish a recommended dose of INCB081776 as a monotherapy (Part 1) and then in combination with INCMGA00012 (Part 2) in participants with advanced malignancies. During…

A Phase 1, Open-Label, multicenter Study of INCA00186 as monotherapy or in combination with immunotherapy in participants with advanced solid tumors

The primary objective is to evaluate the safety, tolerability, and doselimiting toxicities, and determine the recommended dose for expansionof INCA00186 as monotherapy and of combination treatments of INCA00186 with retifanlimab and/or INCB106385 in…

An open label pilot study of [18F]AlF-RESCA-IL2 (Interleukin-2 PET tracer) for positron emission tomography imaging in patients treated with immune checkpoint inhibitors

Primary objectives:• To evaluate safety of repeat doses of [18F]AlF-RESCA-IL2.• To evaluate tumour uptake of [18F]AlF-RESCA-IL2 in patients with cancer.• To evaluate whole body distribution of [18F]AlF-RESCA-IL2 in cancer patients.Secondary…

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

This study has been transitioned to CTIS with ID 2024-512822-28-00 check the CTIS register for the current data. The primary objective of this study is to evaluate the safety and tolerability and determine the MTD and RDE(s) of INCB123667 as…

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

This study has been transitioned to CTIS with ID 2024-516938-34-00 check the CTIS register for the current data. The primary objective of this study is to evaluate the rate of ongoing response at 12 months after start of treatment in patients with…

Validation of ICG-99mTc-nanoscan as hybrid tracer for sentinel node biopsy

This study has been transitioned to CTIS with ID 2024-519351-28-00 check the CTIS register for the current data. Cross validation of the hybrid tracer ICG 99 Tc Nanoscan with respect to 99m Tc Nanoscan for the determination. In particular the…

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

This study has been transitioned to CTIS with ID 2023-506384-34-00 check the CTIS register for the current data. Primary:- To assess the safety and tolerability of MK2140- To evaluate objective response rate (ORR) of MK2140 as assessed by BICR per…

Cancer aftercare in general practice - A blended lifestyle medicine approach

The primary objective of this research is to gain insight into the short term (6 months) and long term (12 months) effects of the blended care protocol on cancer survivors* lifestyle behaviours. The secondary goal of this research is to gain insight…

Individualisation of management with novel upfront therapy enzalutamide in newly diagnosed metastasized prostate cancer using (PSMA)PET/CT imaging

To assess the predictive value of early response measurements on PSMA-PET/CT for therapy success, defined as time to development of castration-resistant prostate cancer (CRPC), in order to personalize treatment choice.

Distribution, dosimetry and imaging of [195mPt]cisplatin in cancer patients

Investigate the distribution, dosimetry and image quality of [195mPt]cisplatin in cancer patients

Detecting cancers Earlier Through Elective plasma-based CancerSEEK
Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic
II (DETECT-ASCEND 2)

The primary objective of this study is to obtain clinically characterized, whole blood specimens from subjects with a new or suspected diagnosis of cancer (cancer subjects) and from subjects who do not have a diagnosis of cancer (healthy) to develop…